Cancer vaccines

R. T. Reilly, J. P H Machiels, Elizabeth Jaffee

Research output: Contribution to journalArticle

Abstract

Immunotherapy is an alternative to more traditional forms of anticancer therapy that has the ability to activate tumour-specific humoral and cellular immune responses. As immunotherapeutic effects occur via mechanisms that are distinct from traditional therapies, such as surgery, radiotherapy and chemotherapy, cancer vaccines represent an additional treatment option with an entirely different spectrum of toxicities. This allows for the use of immunotherapy in conjunction with existing treatment options. This review describes several recent antitumour vaccines that employ whole tumour cells, antigen mimicry, antigen-pulsed dendritic cells and recombinant viruses to deliver antigen for the generation of an effective antitumour immune response. With an improved understanding of tumour immunology as well as the events that are required to generate an optimal immune response, the possibility of designing effective cancer vaccine approaches that induce both humoral and cellular responses has become even more realistic.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalEmerging Drugs
Volume5
Issue number2
StatePublished - 2000

Fingerprint

Cancer Vaccines
Immunotherapy
Molecular Mimicry
Antigens
Neoplasm Antigens
Therapeutics
Humoral Immunity
Allergy and Immunology
Cellular Immunity
Dendritic Cells
Neoplasms
Radiotherapy
Vaccines
Viruses
Drug Therapy

Keywords

  • Allogeneic vaccine
  • Anti-idiotype vaccine
  • Antigen
  • Antigen mimicry
  • Autologous vaccine
  • Cancer vaccine
  • Dendritic cell
  • Recombinant virus

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Reilly, R. T., Machiels, J. P. H., & Jaffee, E. (2000). Cancer vaccines. Emerging Drugs, 5(2), 201-209.

Cancer vaccines. / Reilly, R. T.; Machiels, J. P H; Jaffee, Elizabeth.

In: Emerging Drugs, Vol. 5, No. 2, 2000, p. 201-209.

Research output: Contribution to journalArticle

Reilly, RT, Machiels, JPH & Jaffee, E 2000, 'Cancer vaccines', Emerging Drugs, vol. 5, no. 2, pp. 201-209.
Reilly RT, Machiels JPH, Jaffee E. Cancer vaccines. Emerging Drugs. 2000;5(2):201-209.
Reilly, R. T. ; Machiels, J. P H ; Jaffee, Elizabeth. / Cancer vaccines. In: Emerging Drugs. 2000 ; Vol. 5, No. 2. pp. 201-209.
@article{ef1f3e36c4e44c9880b510a701a835e8,
title = "Cancer vaccines",
abstract = "Immunotherapy is an alternative to more traditional forms of anticancer therapy that has the ability to activate tumour-specific humoral and cellular immune responses. As immunotherapeutic effects occur via mechanisms that are distinct from traditional therapies, such as surgery, radiotherapy and chemotherapy, cancer vaccines represent an additional treatment option with an entirely different spectrum of toxicities. This allows for the use of immunotherapy in conjunction with existing treatment options. This review describes several recent antitumour vaccines that employ whole tumour cells, antigen mimicry, antigen-pulsed dendritic cells and recombinant viruses to deliver antigen for the generation of an effective antitumour immune response. With an improved understanding of tumour immunology as well as the events that are required to generate an optimal immune response, the possibility of designing effective cancer vaccine approaches that induce both humoral and cellular responses has become even more realistic.",
keywords = "Allogeneic vaccine, Anti-idiotype vaccine, Antigen, Antigen mimicry, Autologous vaccine, Cancer vaccine, Dendritic cell, Recombinant virus",
author = "Reilly, {R. T.} and Machiels, {J. P H} and Elizabeth Jaffee",
year = "2000",
language = "English (US)",
volume = "5",
pages = "201--209",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Cancer vaccines

AU - Reilly, R. T.

AU - Machiels, J. P H

AU - Jaffee, Elizabeth

PY - 2000

Y1 - 2000

N2 - Immunotherapy is an alternative to more traditional forms of anticancer therapy that has the ability to activate tumour-specific humoral and cellular immune responses. As immunotherapeutic effects occur via mechanisms that are distinct from traditional therapies, such as surgery, radiotherapy and chemotherapy, cancer vaccines represent an additional treatment option with an entirely different spectrum of toxicities. This allows for the use of immunotherapy in conjunction with existing treatment options. This review describes several recent antitumour vaccines that employ whole tumour cells, antigen mimicry, antigen-pulsed dendritic cells and recombinant viruses to deliver antigen for the generation of an effective antitumour immune response. With an improved understanding of tumour immunology as well as the events that are required to generate an optimal immune response, the possibility of designing effective cancer vaccine approaches that induce both humoral and cellular responses has become even more realistic.

AB - Immunotherapy is an alternative to more traditional forms of anticancer therapy that has the ability to activate tumour-specific humoral and cellular immune responses. As immunotherapeutic effects occur via mechanisms that are distinct from traditional therapies, such as surgery, radiotherapy and chemotherapy, cancer vaccines represent an additional treatment option with an entirely different spectrum of toxicities. This allows for the use of immunotherapy in conjunction with existing treatment options. This review describes several recent antitumour vaccines that employ whole tumour cells, antigen mimicry, antigen-pulsed dendritic cells and recombinant viruses to deliver antigen for the generation of an effective antitumour immune response. With an improved understanding of tumour immunology as well as the events that are required to generate an optimal immune response, the possibility of designing effective cancer vaccine approaches that induce both humoral and cellular responses has become even more realistic.

KW - Allogeneic vaccine

KW - Anti-idiotype vaccine

KW - Antigen

KW - Antigen mimicry

KW - Autologous vaccine

KW - Cancer vaccine

KW - Dendritic cell

KW - Recombinant virus

UR - http://www.scopus.com/inward/record.url?scp=0033917824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033917824&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033917824

VL - 5

SP - 201

EP - 209

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -